
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is a pioneering company in the field of artificial intelligence powered synthetic biology, with a strong focus on the potential of proteins as the next generation of therapeutics. With its lead product candidate ABS-201 showing promising results in early studies and a partnership with Eli Lilly, Absci is well-positioned for success in developing novel biologics. The company's diverse pipeline and partnerships provide additional potential for growth, ensuring it remains a strong contender in the competitive landscape of ML/AI drug discovery.
Bears say
Absci is conducting trials on their lead product candidate, ABS-201, to determine the optimal dosing for patient-friendly administration, with interim PK data suggesting a half-life of ≥65 days and the potential for 2-3 doses over a six-month period. While initial safety data is favorable, the lack of efficacy data and potential for more frequent administration may affect the drug's commercial viability and future profitability.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares